Our Advantage

An impressive history

CMAX is Australia’s longest established, independent facility for the conduct of early-phase clinical trials.  CMAX is recognised as one of Australia’s most experienced service providers delivering high quality, internationally approved data which meets all regulatory requirements.

Our modern custom-built facility opened in 2016 opposite the Royal Adelaide Hospital and adjacent to Adelaide’s brand-new Bio--Med City.

Adelaide Bio-Med City is one of the largest health and life sciences clusters in the southern hemisphere, providing ready access to state-of-the-art facilities, equipment and world-class medical and pharmacology specialists. CMAX holds long-established relationships with medical specialists across all of these institutions.

Since 1993 we have designed and delivered more than 600 early phase clinical trials, including more than 100 first in human studies for our clients including pharmaceutical, biotechnology and device companies.

CMAX has an impressive global regulatory history. We are US FDA audited and our studies are ICH GCP compliant. Our studies also comply with the registration requirements of the EMA, Japan’s PMDA and Health Canada.

Our services are eligible for the Australian R&D Tax Incentive scheme. This scheme allows eligible companies to claim up to a 43.5%* rebate on qualifying R&D spend.

By using the Australian Clinical Trial Notification (CTN) scheme we can assist you fast-track your clinical trial, reducing the time and cost associated with filing an Investigational New Drug (IND) application.

Australian (TGA) clinical trial start-ups are known for being of exceptional quality, faster than US (FDA) trials and, due to government support and tax rebates are very cost competitive.

Studies are initiated on local human research ethics committee (HREC) approval, which occurs typically within six weeks of submission.

*Please note this rebate percentage is subject to change.